blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3076973

EP3076973 - COMBINATIONS OF HISTONE DEACETYLASE INHIBITORS AND IMMUNOMODULATORY DRUGS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  05.03.2021
Database last updated on 05.10.2024
FormerThe patent has been granted
Status updated on  27.03.2020
FormerGrant of patent is intended
Status updated on  24.11.2019
FormerRequest for examination was made
Status updated on  09.10.2019
FormerGrant of patent is intended
Status updated on  24.02.2019
Most recent event   Tooltip15.07.2022Lapse of the patent in a contracting state
New state(s): BE		published on 17.08.2022  [2022/33]
Applicant(s)For all designated states
Acetylon Pharmaceuticals, Inc.
70 Fargo Street, Suite 205
Boston, MA 02210 / US
[2016/41]
Inventor(s)01 / QUAYLE, Steven, Norman
62 Linden Street
1, Brookline, MA 02445 / US
02 / JONES, Simon, Stewart
46 Westcott Road
Harvard, MA 01451 / US
 [2019/52]
Former [2016/41]01 / QUAYLE, Steven, Norman
62 Linden Street 1
Brookline, MA 02445 / US
02 / JONES, Simon, Stewart
46 Westcott Road
Harvard, MA 01451 / US
Representative(s)Boult Wade Tennant LLP
Salisbury Square House
8 Salisbury Square
London EC4Y 8AP / GB
[2020/18]
Former [2016/41]Boult Wade Tennant
Verulam Gardens
70 Gray's Inn Road
London WC1X 8BT / GB
Application number, filing date14867332.003.12.2014
[2016/41]
WO2014US68263
Priority number, dateUS201361911086P03.12.2013         Original published format: US 201361911086 P
US201462061368P08.10.2014         Original published format: US 201462061368 P
[2016/41]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2015084905
Date:11.06.2015
Language:EN
[2015/23]
Type: A1 Application with search report 
No.:EP3076973
Date:12.10.2016
Language:EN
The application published by WIPO in one of the EPO official languages on 11.06.2015 takes the place of the publication of the European patent application.
[2016/41]
Type: B1 Patent specification 
No.:EP3076973
Date:29.04.2020
Language:EN
[2020/18]
Search report(s)International search report - published on:KR11.06.2015
(Supplementary) European search report - dispatched on:EP02.08.2017
ClassificationIPC:A61K31/505, A61K31/495, A61K31/16, A61P37/00, A61K31/454, A61K45/06, // A61P35/02
[2017/35]
CPC:
A61K31/505 (EP,KR,US); A61K31/404 (KR); A61K31/4439 (KR,US);
A61K31/454 (EP,US); A61K45/06 (EP,US); A61P35/00 (EP);
A61P35/02 (EP); A61P37/00 (EP); A61P43/00 (EP) (-)
C-Set:
A61K31/454, A61K2300/00 (US,EP);
A61K31/505, A61K2300/00 (EP,US)
Former IPC [2016/41]A61K31/505, A61K31/495, A61K31/16, A61P37/00
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2016/41]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:KOMBINATIONEN AUS HISTONDEACTYLASEINHIBITOREN UND IMMUNMODULATORISCHEN ARZNEIMITTELN[2016/41]
English:COMBINATIONS OF HISTONE DEACETYLASE INHIBITORS AND IMMUNOMODULATORY DRUGS[2016/41]
French:COMBINAISONS D'INHIBITEURS D'HISTONE DÉSACÉTYLASE ET MÉDICAMENTS IMMUNOMODULATEURS[2016/41]
Entry into regional phase01.07.2016National basic fee paid 
01.07.2016Search fee paid 
01.07.2016Designation fee(s) paid 
01.07.2016Examination fee paid 
Examination procedure01.07.2016Examination requested  [2016/41]
23.02.2018Amendment by applicant (claims and/or description)
25.02.2019Communication of intention to grant the patent
13.08.2019Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time
09.10.2019Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
25.11.2019Communication of intention to grant the patent
20.03.2020Fee for grant paid
20.03.2020Fee for publishing/printing paid
20.03.2020Receipt of the translation of the claim(s)
Opposition(s)01.02.2021No opposition filed within time limit [2021/14]
Request for further processing for:The application is deemed to be withdrawn due to failure to fulfill actions required for granting the patent
09.10.2019Request for further processing filed
09.10.2019Full payment received (date of receipt of payment)
Request granted
16.10.2019Decision despatched
Fees paidRenewal fee
13.12.2016Renewal fee patent year 03
27.12.2017Renewal fee patent year 04
31.12.2018Renewal fee patent year 05
27.12.2019Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU03.12.2014
AL29.04.2020
AT29.04.2020
CY29.04.2020
CZ29.04.2020
DK29.04.2020
EE29.04.2020
FI29.04.2020
HR29.04.2020
IT29.04.2020
LT29.04.2020
LV29.04.2020
MC29.04.2020
MK29.04.2020
MT29.04.2020
NL29.04.2020
PL29.04.2020
RO29.04.2020
RS29.04.2020
SE29.04.2020
SI29.04.2020
SK29.04.2020
SM29.04.2020
TR29.04.2020
BG29.07.2020
NO29.07.2020
GR30.07.2020
IS29.08.2020
PT31.08.2020
IE03.12.2020
LU03.12.2020
BE31.12.2020
[2022/33]
Former [2022/32]HU03.12.2014
AL29.04.2020
AT29.04.2020
CY29.04.2020
CZ29.04.2020
DK29.04.2020
EE29.04.2020
FI29.04.2020
HR29.04.2020
IT29.04.2020
LT29.04.2020
LV29.04.2020
MC29.04.2020
MK29.04.2020
MT29.04.2020
NL29.04.2020
PL29.04.2020
RO29.04.2020
RS29.04.2020
SE29.04.2020
SI29.04.2020
SK29.04.2020
SM29.04.2020
TR29.04.2020
BG29.07.2020
NO29.07.2020
GR30.07.2020
IS29.08.2020
PT31.08.2020
IE03.12.2020
LU03.12.2020
Former [2022/27]HU03.12.2014
AL29.04.2020
AT29.04.2020
CY29.04.2020
CZ29.04.2020
DK29.04.2020
EE29.04.2020
FI29.04.2020
HR29.04.2020
IT29.04.2020
LT29.04.2020
LV29.04.2020
MC29.04.2020
MT29.04.2020
NL29.04.2020
PL29.04.2020
RO29.04.2020
RS29.04.2020
SE29.04.2020
SI29.04.2020
SK29.04.2020
SM29.04.2020
TR29.04.2020
BG29.07.2020
NO29.07.2020
GR30.07.2020
IS29.08.2020
PT31.08.2020
IE03.12.2020
LU03.12.2020
Former [2021/47]AL29.04.2020
AT29.04.2020
CZ29.04.2020
DK29.04.2020
EE29.04.2020
FI29.04.2020
HR29.04.2020
IT29.04.2020
LT29.04.2020
LV29.04.2020
MC29.04.2020
NL29.04.2020
PL29.04.2020
RO29.04.2020
RS29.04.2020
SE29.04.2020
SI29.04.2020
SK29.04.2020
SM29.04.2020
BG29.07.2020
NO29.07.2020
GR30.07.2020
IS29.08.2020
PT31.08.2020
IE03.12.2020
LU03.12.2020
Former [2021/46]AL29.04.2020
AT29.04.2020
CZ29.04.2020
DK29.04.2020
EE29.04.2020
FI29.04.2020
HR29.04.2020
IT29.04.2020
LT29.04.2020
LV29.04.2020
MC29.04.2020
NL29.04.2020
PL29.04.2020
RO29.04.2020
RS29.04.2020
SE29.04.2020
SI29.04.2020
SK29.04.2020
SM29.04.2020
BG29.07.2020
NO29.07.2020
GR30.07.2020
IS29.08.2020
PT31.08.2020
IE03.12.2020
Former [2021/40]AL29.04.2020
AT29.04.2020
CZ29.04.2020
DK29.04.2020
EE29.04.2020
FI29.04.2020
HR29.04.2020
IT29.04.2020
LT29.04.2020
LV29.04.2020
MC29.04.2020
NL29.04.2020
PL29.04.2020
RO29.04.2020
RS29.04.2020
SE29.04.2020
SI29.04.2020
SK29.04.2020
SM29.04.2020
BG29.07.2020
NO29.07.2020
GR30.07.2020
IS29.08.2020
PT31.08.2020
Former [2021/24]AL29.04.2020
AT29.04.2020
CZ29.04.2020
DK29.04.2020
EE29.04.2020
FI29.04.2020
HR29.04.2020
IT29.04.2020
LT29.04.2020
LV29.04.2020
NL29.04.2020
PL29.04.2020
RO29.04.2020
RS29.04.2020
SE29.04.2020
SI29.04.2020
SK29.04.2020
SM29.04.2020
BG29.07.2020
NO29.07.2020
GR30.07.2020
IS29.08.2020
PT31.08.2020
Former [2021/10]AL29.04.2020
AT29.04.2020
CZ29.04.2020
DK29.04.2020
EE29.04.2020
FI29.04.2020
HR29.04.2020
IT29.04.2020
LT29.04.2020
LV29.04.2020
NL29.04.2020
PL29.04.2020
RO29.04.2020
RS29.04.2020
SE29.04.2020
SK29.04.2020
SM29.04.2020
BG29.07.2020
NO29.07.2020
GR30.07.2020
IS29.08.2020
PT31.08.2020
Former [2021/09]AL29.04.2020
AT29.04.2020
CZ29.04.2020
DK29.04.2020
EE29.04.2020
FI29.04.2020
HR29.04.2020
IT29.04.2020
LT29.04.2020
LV29.04.2020
NL29.04.2020
RO29.04.2020
RS29.04.2020
SE29.04.2020
SM29.04.2020
BG29.07.2020
NO29.07.2020
GR30.07.2020
IS29.08.2020
PT31.08.2020
Former [2021/08]AL29.04.2020
DK29.04.2020
FI29.04.2020
HR29.04.2020
LT29.04.2020
LV29.04.2020
NL29.04.2020
RO29.04.2020
RS29.04.2020
SE29.04.2020
SM29.04.2020
BG29.07.2020
NO29.07.2020
GR30.07.2020
IS29.08.2020
PT31.08.2020
Former [2021/04]AL29.04.2020
FI29.04.2020
HR29.04.2020
LT29.04.2020
LV29.04.2020
NL29.04.2020
RS29.04.2020
SE29.04.2020
BG29.07.2020
NO29.07.2020
GR30.07.2020
IS29.08.2020
PT31.08.2020
Former [2021/01]FI29.04.2020
HR29.04.2020
LT29.04.2020
LV29.04.2020
RS29.04.2020
SE29.04.2020
BG29.07.2020
NO29.07.2020
GR30.07.2020
IS29.08.2020
PT31.08.2020
Former [2020/51]FI29.04.2020
HR29.04.2020
LT29.04.2020
LV29.04.2020
RS29.04.2020
SE29.04.2020
NO29.07.2020
GR30.07.2020
IS29.08.2020
PT31.08.2020
Former [2020/50]FI29.04.2020
HR29.04.2020
LT29.04.2020
LV29.04.2020
SE29.04.2020
NO29.07.2020
GR30.07.2020
IS29.08.2020
PT31.08.2020
Former [2020/48]FI29.04.2020
LT29.04.2020
SE29.04.2020
NO29.07.2020
IS29.08.2020
PT31.08.2020
Former [2020/47]LT29.04.2020
NO29.07.2020
IS29.08.2020
Former [2020/46]IS29.08.2020
Documents cited:Search[X]US2009227674  (RICHON VICTORIA M [US], et al) [X] 1,10-15 * [0005], [0022] [0025]; Fig. 1 *;
 [XY]US2012190693  (VAN DUZER JOHN H [US], et al) [X] 1,10-15 * claims 12, 15; claim 9, first compound; last compound on p. 79; p. 30, third compound *[Y] 1-7,10-15;
 [A]WO2013041480  (SIGMA TAU IND FARMACEUTI [IT]) [A] 1-3,10-15 * see p. 36, table 1 *;
 [X]  - GARDNER J M ET AL, "A novel regimen of vorinostat with interferon gamma for refractory Sezary syndrome", JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, MOSBY, INC, US, vol. 61, no. 1, doi:10.1016/J.JAAD.2008.11.889, ISSN 0190-9622, (20090701), pages 112 - 116, (20090617), XP026336032 [X] 1,10-15 * abstract *

DOI:   http://dx.doi.org/10.1016/j.jaad.2008.11.889
 [XY]  - TINT LWIN ET AL, "A microenvironment-mediated c-Myc/miR-548m/HDAC6 amplification loop in non-Hodgkin B cell lymphomas", JOURNAL OF CLINICAL INVESTIGATION, US, (20131101), vol. 123, no. 11, doi:10.1172/JCI64210, ISSN 0021-9738, pages 4612 - 4626, XP055389682 [X] 1,10-15 * title, abstract; p. 4613, first §; Fig. 5D * [Y] 1-7,10-15

DOI:   http://dx.doi.org/10.1172/JCI64210
 [A]  - P Porcu ET AL, "Bexarotene-Induced T-Cell Immunomodulation and Response in CTCL. | Blood Journal", Blood 2004 104:744, (20040101), URL: http://www.bloodjournal.org/content/104/11/744, (20170711), XP055389612 [A] 1-7,10-15 * title, abstract *
 [Y]  - J Amengual, "Dual Targeting of Protein Degradation Pathways with the Selective HDAC6 Inhibitor Rocilinostat (ACY-1215) and Bortezomib, Demonstrates Synergistic Antitumor Activity in Preclinical Models of Lymphoma | Blood Journal", Blood 2012 120:1650, (20120101), URL: http://www.bloodjournal.org/content/120/21/1650?sso-checked=true, (20170710), XP055389512 [Y] 1-7,10-15 * abstract *
 [XI]  - Eva Sahakian ET AL, "Combination of ACY1215, a Selective Histone Deacetylase 6 (HDAC6) Inhibitor with the Bruton Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, Represents a Novel Therapeutic Strategy in Mantle Cell Lymphoma (MCL) | Blood Journal", Blood, (20120101), URL: http://www.bloodjournal.org/content/120/21/1660?sso-checked=true, (20170407), XP055363021 [X] 1-3 * abstract * [I] 1-7,10-15
 [A]  - Rohit Ghurye ET AL, "BET bromodomain inhibition by JQ1 suppresses interleukin-6 secretion in myeloma cells", (20130822), URL: http://www.frontiersin.org/10.3389/conf.fimmu.2013.02.00823/event_abstract, (20170710), XP055389460 [A] 1-7,9-15 * abstract *

DOI:   http://dx.doi.org/10.3389/conf.fimmu.2013.02.00823
 [A]  - SCOTT L J ET AL, "Mitoxantrone: A review of its use in multiple sclerosis", EMBASE, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, (2004), Database accession no. EMB-2004210614, XP002771975 [A] 1-7,9-15 * abstract *
International search[Y]US2010098657  (SCHAFER PETER H [US], et al);
 [A]US2011280849  (ZHANG XIAOKUI [US], et al);
 [X]US2012121502  (VAN DUZER JOHN H [US], et al);
 [A]WO2013013113  (GEN HOSPITAL CORP [US], et al);
 [X]US2013225543  (JONES SIMON S [US], et al)
by applicantUS5635517
 US6281230
 US6335349
 US6476052
    - TINT LWIN et al., "A microenvironment-mediated c-Myc/miR-548m/HDAC6 amplification loop in non-Hodgkin B cell lymphomas", Journal of Clinical Investigation, (20131101), vol. 123, no. 11, doi:doi:10.1172/JCI64210, ISSN 0021-9738, pages 4612 - 4626, XP055389682

DOI:   http://dx.doi.org/10.1172/JCI64210
    - J AMENGUAL, Blood Journal, Blood, (20120101), vol. 120, page 1650
    - SAHAKIAN EVA et al., Blood & 54th annual meeting and exposition of the American-Society-of-hematology (Ash), (20121100), vol. 120, no. 21, page 1660, XP055363021
    - Remington's Pharmaceutical Sciences, Mack Publishing Company, (19850000), page 1418
    - Journal of Pharmaceutical Science, (19770000), vol. 66, no. 2
    - HOLFORD, N. H. G.; SCHEINER, L. B., Clin. Pharmacokinet., (19810000), vol. 6, pages 429 - 453
    - LOEWE, S.; MUISCHNEK, H., Arch. Exp. Pathol Pharmacol., (19260000), vol. 114, pages 313 - 326
    - CHOU, T. C.; TALALAY, P., Adv. Enzyme Regul., (19840000), vol. 22, pages 27 - 55
 WO1997US13375
 WO2011US21982
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.